anti-CD19 CAR T-cell therapy (Memorial Sloan Kettering Cancer Center)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (Memorial Sloan Kettering Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin 18 receptor modulatorsImmunostimulantsB-lymphocyte antigen CD19 modulators +[4]

TargetsInterleukin 18 receptorB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesMemorial Sloan Kettering Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A